drugset / Trial / NCT02791373

Vinorelbine and Gemcitabine in Myeloma

NCT02791373

Phase 2 Completed 136 enrolled Insel Gruppe AG, University Hospital Bern
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether the efficacy of gemcitabine is comparable with the efficacy of the standard chemotherapy with vinorelbine for mobilization of autologous stem cells in myeloma patients

Timeline

Start
2014-03
Primary completion
2017-12-31
Completion
2017-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule 1250 mg/m2 Intravenous
Comparator Vinorelbine Small molecule 35 mg/m2 Intravenous